5,8-Dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine; hydrochloride | 66341-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 5,8-Dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine; hydrochloride
• 英文别名: 2-Naphthalenamine, 1,2,3,4-tetrahydro-5,8-dimethoxy-, hydrochloride；5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride
• CAS: 66341-15-9
• 化学式: C₁₂H₁₇NO₂*ClH
• 分子量: 243.733
• InChiKey: JYJRXFMEQVPVGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.94
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,8-Dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine; hydrochloride 在 diborane(6) 作用下， 生成 (5,8-二甲氧基-1,2,3,4-四氢-萘-2-基)-丙基-胺盐酸盐
  参考文献：
  名称：

  .alpha.-Adrenergic agents. 2. Synthesis and .alpha.1-agonist activity of 2-aminotetralins

  摘要：

  Substituted 2-aminotetralins are potent, selective, direct-acting agonists at postjunctional alpha 1 receptors. Within this series, substituent alterations on the ring, as well as on the nitrogen, change the potency of compounds by over three orders of magnitude (EC50 = 12 to greater than 10 000 nM). It has been demonstrated experimentally that substitution at both the 5 and 8 positions of the aromatic ring produces optimum agonist potency. Removal of either substituent results in a loss of potency and efficacy relative to norepinephrine. Substitution at positions 6 and/or 7 is generally detrimental to activity. Methyl, ethyl, or dimethyl substitution on nitrogen is compatible with high agonist potency, while substitution with larger groups is not. The most potent agonist in this series is 5-(thiomethyl)-8-methoxy-2-aminotetralin, which has an EC50 of 12 nM.

  DOI：

  10.1021/jm00344a009
• 作为产物：
  描述：

  2-amino-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol 以64%的产率得到
  参考文献：
  名称：

  DELGADO, ANTONIO;MAULEON, DAVID;ROSELL, GLORIA;GRANADOS, RICARDO, EUR. J. MED. CHEM., 23,(1988) N 1, 31-38

  摘要：

  DOI：

文献信息

• AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
  申请人：ATAI Life Sciences AG

  公开号：US20230202965A1

  公开（公告）日：2023-06-29

  Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

  本文提供了公式(I)、(I-A)、(I-B)、(II)、(II-A)、(II-B)、(III)、(III-A)、(IV)和(IV-A)的化合物，或其药学上可接受的盐。本文还提供了包含化合物公式(I)、(I-A)、(I-B)、(II)、(II-A)、(II-B)、(III)、(III-A)、(IV)和(IV-A)或其药学上可接受的盐的制药组合物，并提供了使用公式(I)、(I-A)、(I-B)、(II)、(II-A)、(II-B)、(III)、(III-A)、(IV)和(IV-A)或其药学上可接受的盐的方法，例如用于治疗精神健康疾病或障碍。
• Synthesis and adrenergic properties of cyclic analogues of methoxamine: 2-amino-1-arylcyclohexanols and 2-amino-1,2,3,4-tetrahydro-1-naphthalenols
  作者：Antonio Delgado、David Mauleón、Gloria Rosell、Ricardo Granados

  DOI：10.1016/0223-5234(88)90164-x

  日期：1988.1
• DELGADO, ANTONIO;MAULEON, DAVID;ROSELL, GLORIA;GRANADOS, RICARDO, EUR. J. MED. CHEM., 23,(1988) N 1, 31-38
  作者：DELGADO, ANTONIO、MAULEON, DAVID、ROSELL, GLORIA、GRANADOS, RICARDO

  DOI：——

  日期：——
• AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF
  申请人：ZENECA LIMITED

  公开号：EP0883599A1

  公开（公告）日：1998-12-16
• [EN] AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF<br/>[FR] DERIVES DE L'AMINOTETRALINE, COMPOSITIONS CONTENANT CES DERIVES ET METHODES POUR LES UTILISER
  申请人：ZENECA LIMITED

  公开号：WO1997031887A1

  公开（公告）日：1997-09-04

  (EN) The invention relates to aminotetralin derivatives of formula (I) wherein: R1 is methyl or ethyl; R2 is hydrogen, halogen, lower-alkoxy or thiolower-alkyl; R3 is hydrogen, halogen, lower-alkoxy or lower-alkyl; and the chiral center * is in the (S)(-) form; or a pharmaceutically acceptable acid-addition salt thereof, with the proviso that when R2 and R3 are both hydrogen, R1 must be methyl; to pharmaceutical compositions containing them and to methods for the treatment or prevention of movement disorders utilizing them.(FR) L'invention concerne des dérivés de l'aminotétraline de la formule (I). Dans cette formule, R1 est un méthyle ou un éthyle; R2 est un hydrogène, halogène, alcoxy inférieur ou thioalkyle inférieur; R3 est un hydrogène, halogène, alcoxy inférieur ou alkyle inférieur; et le centre chiral * a la forme (S)(-). L'invention concerne, également, un sel d'addition obtenu avec un acide acceptable sur le plan pharmaceutique. Une condition à satisfaire est que, quand R2 et R3 sont tous deux des hydrogènes, R1 doit être un méthyle. L'invention concerne également des compositions pharmaceutiques contenant ces dérivés et des méthodes de traitement ou de prévention de troubles moteurs faisant appel à eux.